Savara (NASDAQ:SVRA) Stock Price Down 3.4% – Time to Sell?

Savara Inc (NASDAQ:SVRA)’s share price traded down 3.4% on Wednesday . The company traded as low as $3.63 and last traded at $3.65. 275,688 shares traded hands during trading, a decline of 77% from the average session volume of 1,204,978 shares. The stock had previously closed at $3.78.

Wall Street Analyst Weigh In

SVRA has been the topic of several research analyst reports. Oppenheimer upped their target price on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday, June 26th. JMP Securities reissued a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Savara in a research note on Tuesday. Finally, Guggenheim increased their price objective on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Savara has an average rating of “Buy” and an average price target of $11.17.

Savara Trading Down 3.4 %

The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $504.39 million, a P/E ratio of -9.86 and a beta of 0.96. The firm’s 50-day moving average price is $4.26 and its 200 day moving average price is $4.42.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). As a group, equities research analysts predict that Savara Inc will post -0.44 earnings per share for the current year.

Institutional Trading of Savara

Institutional investors and hedge funds have recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co bought a new stake in Savara in the 1st quarter worth about $35,000. Choreo LLC bought a new position in shares of Savara in the second quarter valued at approximately $59,000. DRW Securities LLC bought a new position in shares of Savara in the second quarter valued at approximately $62,000. Principal Financial Group Inc. increased its position in shares of Savara by 64.4% during the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the last quarter. Finally, ProShare Advisors LLC lifted its holdings in Savara by 9.0% during the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after acquiring an additional 2,114 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.